Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Anne Ségolène Cottereau, Annibale Versari, Annika Loft, Olivier Casasnovas, Monica Bellei, Romain Ricci, Stéphane Bardet, Antonio Castagnoli, Pauline Brice, John Raemaekers, Bénédicte Deau, Catherine Fortpied, Tiana Raveloarivahy, Emelie Van Zele, Loic Chartier, Thierry Vander Borght, Massimo Federico, Martin Hutchings, Umberto Ricardi, Marc AndreMichel Meignan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P 5 .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n 5 46), respectively, vs 92% and 98% in the low-TMTV group (£147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV£1471DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>1471DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV£1471DS4-5; 5-year PFS, 50%), and high (TMTV>1471DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. (Blood. 2018;131(13):1456-1463)

Original languageEnglish
Pages (from-to)1456-1463
Number of pages8
JournalBlood
Volume131
Issue number13
DOIs
Publication statusPublished - Mar 29 2018

Fingerprint

Tumor Burden
Hodgkin Disease
Tumors
Positron emission tomography
Disease-Free Survival
Positron-Emission Tomography
Dacarbazine
Vinblastine
Bleomycin
Doxorubicin
Tomography
Neoplasms
Blood
Survival
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. / Cottereau, Anne Ségolène; Versari, Annibale; Loft, Annika; Casasnovas, Olivier; Bellei, Monica; Ricci, Romain; Bardet, Stéphane; Castagnoli, Antonio; Brice, Pauline; Raemaekers, John; Deau, Bénédicte; Fortpied, Catherine; Raveloarivahy, Tiana; Van Zele, Emelie; Chartier, Loic; Borght, Thierry Vander; Federico, Massimo; Hutchings, Martin; Ricardi, Umberto; Andre, Marc; Meignan, Michel.

In: Blood, Vol. 131, No. 13, 29.03.2018, p. 1456-1463.

Research output: Contribution to journalArticle

Cottereau, AS, Versari, A, Loft, A, Casasnovas, O, Bellei, M, Ricci, R, Bardet, S, Castagnoli, A, Brice, P, Raemaekers, J, Deau, B, Fortpied, C, Raveloarivahy, T, Van Zele, E, Chartier, L, Borght, TV, Federico, M, Hutchings, M, Ricardi, U, Andre, M & Meignan, M 2018, 'Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial', Blood, vol. 131, no. 13, pp. 1456-1463. https://doi.org/10.1182/blood-2017-07-795476
Cottereau, Anne Ségolène ; Versari, Annibale ; Loft, Annika ; Casasnovas, Olivier ; Bellei, Monica ; Ricci, Romain ; Bardet, Stéphane ; Castagnoli, Antonio ; Brice, Pauline ; Raemaekers, John ; Deau, Bénédicte ; Fortpied, Catherine ; Raveloarivahy, Tiana ; Van Zele, Emelie ; Chartier, Loic ; Borght, Thierry Vander ; Federico, Massimo ; Hutchings, Martin ; Ricardi, Umberto ; Andre, Marc ; Meignan, Michel. / Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. In: Blood. 2018 ; Vol. 131, No. 13. pp. 1456-1463.
@article{9e2a5079994041aaab1ae9b84fa3c34e,
title = "Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial",
abstract = "We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P 5 .0001), with 86{\%} and 84{\%} specificity, respectively. Five-year PFS and OS were 71{\%} and 83{\%} in the high-TMTV (>147 cm3) group (n 5 46), respectively, vs 92{\%} and 98{\%} in the low-TMTV group (£147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV£1471DS1-3; 5-year PFS, 95{\%}), low-intermediate (TMTV>1471DS1-3; 5-year PFS, 81.6{\%}), high-intermediate (TMTV£1471DS4-5; 5-year PFS, 50{\%}), and high (TMTV>1471DS4-5; 5-year PFS, 25{\%}). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. (Blood. 2018;131(13):1456-1463)",
author = "Cottereau, {Anne S{\'e}gol{\`e}ne} and Annibale Versari and Annika Loft and Olivier Casasnovas and Monica Bellei and Romain Ricci and St{\'e}phane Bardet and Antonio Castagnoli and Pauline Brice and John Raemaekers and B{\'e}n{\'e}dicte Deau and Catherine Fortpied and Tiana Raveloarivahy and {Van Zele}, Emelie and Loic Chartier and Borght, {Thierry Vander} and Massimo Federico and Martin Hutchings and Umberto Ricardi and Marc Andre and Michel Meignan",
year = "2018",
month = "3",
day = "29",
doi = "10.1182/blood-2017-07-795476",
language = "English",
volume = "131",
pages = "1456--1463",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

AU - Cottereau, Anne Ségolène

AU - Versari, Annibale

AU - Loft, Annika

AU - Casasnovas, Olivier

AU - Bellei, Monica

AU - Ricci, Romain

AU - Bardet, Stéphane

AU - Castagnoli, Antonio

AU - Brice, Pauline

AU - Raemaekers, John

AU - Deau, Bénédicte

AU - Fortpied, Catherine

AU - Raveloarivahy, Tiana

AU - Van Zele, Emelie

AU - Chartier, Loic

AU - Borght, Thierry Vander

AU - Federico, Massimo

AU - Hutchings, Martin

AU - Ricardi, Umberto

AU - Andre, Marc

AU - Meignan, Michel

PY - 2018/3/29

Y1 - 2018/3/29

N2 - We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P 5 .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n 5 46), respectively, vs 92% and 98% in the low-TMTV group (£147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV£1471DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>1471DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV£1471DS4-5; 5-year PFS, 50%), and high (TMTV>1471DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. (Blood. 2018;131(13):1456-1463)

AB - We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P 5 .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n 5 46), respectively, vs 92% and 98% in the low-TMTV group (£147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV£1471DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>1471DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV£1471DS4-5; 5-year PFS, 50%), and high (TMTV>1471DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. (Blood. 2018;131(13):1456-1463)

UR - http://www.scopus.com/inward/record.url?scp=85047511662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047511662&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-07-795476

DO - 10.1182/blood-2017-07-795476

M3 - Article

AN - SCOPUS:85047511662

VL - 131

SP - 1456

EP - 1463

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -